Advocate Group LLC Sells 8,297 Shares of Pfizer Inc. $PFE

Advocate Group LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 345,375 shares of the biopharmaceutical company’s stock after selling 8,297 shares during the period. Pfizer accounts for approximately 1.5% of Advocate Group LLC’s investment portfolio, making the stock its 23rd biggest position. Advocate Group LLC’s holdings in Pfizer were worth $8,372,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Vanguard Personalized Indexing Management LLC raised its position in Pfizer by 26.4% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 504,446 shares of the biopharmaceutical company’s stock worth $12,230,000 after purchasing an additional 105,453 shares during the last quarter. Concurrent Investment Advisors LLC grew its holdings in Pfizer by 11.5% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 200,775 shares of the biopharmaceutical company’s stock worth $4,867,000 after acquiring an additional 20,663 shares during the period. Inman Jager Wealth Management LLC grew its holdings in Pfizer by 14.7% during the 2nd quarter. Inman Jager Wealth Management LLC now owns 40,084 shares of the biopharmaceutical company’s stock worth $972,000 after acquiring an additional 5,124 shares during the period. Fifth Third Wealth Advisors LLC grew its holdings in Pfizer by 20.6% during the 2nd quarter. Fifth Third Wealth Advisors LLC now owns 145,041 shares of the biopharmaceutical company’s stock worth $3,516,000 after acquiring an additional 24,756 shares during the period. Finally, Richardson Financial Services Inc. grew its stake in shares of Pfizer by 14.6% in the 2nd quarter. Richardson Financial Services Inc. now owns 4,762 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 605 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

Pfizer stock opened at $24.81 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.82. The company’s 50 day moving average price is $24.86 and its two-hundred day moving average price is $24.13. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock has a market cap of $141.03 billion, a P/E ratio of 13.19, a P/E/G ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is 91.49%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on PFE. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. UBS Group reiterated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday. Bank of America boosted their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Finally, Citigroup raised their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $28.35.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.